The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.
Report Scope:
The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.
Report Includes:
- An overview of the global markets for cancer immunotherapies and oncolytic virology.
- Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation.
- Information covering the latest trends, market structure, market size, key drug segments, and trends in technology.
- Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products.
- Technological discussions, including the current state, newly issued patents, and pending applications.
- Profiles of leading companies in the industry.
Report Summary
Cancer is a disease with global implications. There are many different types of cancer, of which the most common types include lung, breast, colon and rectal, stomach, head and neck, prostate, cervical, melanoma, and ovarian cancer, as well as leukemia. Cancer is a genetic disease that is conventionally treated by surgery, radiation therapy, chemotherapy, hormonal therapy, and immunotherapy. Surgery is the mainstay treatment for all cancers. Usually surgery is complimented with radiation or chemotherapy to ensure the clearance of all residual cancer. Despite the advances in treatment, cancer has great plasticity; therefore, after a certain time the effects of treatment fade and cancer returns with acquired resistance. Combination therapy, using multiple modalities including surgery and pharmaceutical or radiation therapy, improves response to treatment.
Radiation and chemotherapy have many side effects. Biological treatment options provide less impactful treatment of cancer. Immunotherapy is a type of biological therapy and it incorporates elements of the immune system in cancer treatment. The immune system has various types of cells and proteins that detect and act upon signs of a disease or infection by harmful and foreign substances such as microbes, bacteria and viruses. The immune system differentiates the body’s own cells and tissues through an evolutionary bar-coding system. This system helps the immune system understand encountered foreign substances as “nonself.” Cancer cells are recognized as nonself as well. The immune system monitors the body for cancer and destroys when it detects a malignancy. Cancer cells can avoid being recognized by the immune system and develop resistance through numerous methods.
Since the early 1900s, the connection between cancer and the immune system has caught the attention of various scientists and medical practitioners. Although the early studies were bluntly done without current technological and scientific tools, they nonetheless shed insights leading to the development of the first monoclonal antibodies and to the use of biologically derived synthetic interleukins and interferons. After many decades of research, immunotherapy finally emerged as a fully functional
clinical area in the 1990s. Since then, the cancer therapeutics landscape has changed dramatically.
With the stream of product approvals in recent years, the global immunotherapy market has reached its current value. In 2015, the global cancer immunotherapy market hit $65 billion. The current immunotherapy market contains several blockbuster products reaching their end-of-market exclusivities; however, the market is mostly comprised of newly introduced and expensive therapies. In 2016, the market expanded by more than 10% over the previous year, reaching $73 billion. During the period of 2016 through 2021, the global cancer immunotherapy market is forecast to grow by a 5.7% compound annual growth rate (CAGR), reaching $96.5 billion in 2021.
The strongest growth is expected to occur in checkpoint-inhibitor drugs with a 19.4% CAGR during the forecast period. Immunomodulators are anticipated to show the second-highest growth rates among immunotherapy products, with an 8.4% CAGR during the same period. The combined sales from both segments are expected to make up for nearly one-third of the market, with a combined sales value of $28 billion in 2021. Checkpoint inhibitors are virtually comprised of monoclonal antibodies; however,
they are assessed separately due to their immense commercial and clinical significance. Sales from other therapeutic antibodies accrued to $28 billion in 2016, and this value is expected to remain relatively constant through 2021, due to several patent expiries, pressure from anticipated generic entries, and newly introduced classes of drugs expected by 2021.
Table of Contents
Chapter 1 Introduction
Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of The Study
Information Sources for the Technology Assessment
Forecasting Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Past and Present of Cancer Immunology
What is Cancer?
Cancer as a Genetic Disorder
Treating Cancer
Surgery
Radiation Therapy
Pharmaceutical Therapy
Challenges in Treating Cancer
Cancer and the Immune System
Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Versus Boosting Cancer Immunity
Early Versus Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Diagnosis
Treatment
Prognosis
Breast Cancer
Diagnosis
Treatment
Prognosis
Colorectal Cancer
Diagnosis
Treatment
Prognosis
Stomach Cancer
Diagnosis
Treatment
Prognosis
Head and Neck Cancer
Diagnosis
Treatment
Prognosis
Leukemia
Diagnosis
Treatment
Prognosis
Cervical Cancer
Diagnosis
Treatment
Prognosis
Prostate Cancer
Diagnosis
Treatment
Prognosis
Melanoma of the Skin
Diagnosis
Treatment
Prognosis
Ovarian Cancer
Diagnosis
Treatment
Prognosis
Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology
Chapter 4 Overview of Cancer Immunotherapy
Immune System and Immunotherapy
Therapeutic Monoclonal Antibodies
Checkpoint Inhibitors
Biological Response Modifiers
Interleukin Products
Interferons
Colony-stimulating Factors
Vaccines
Vaccines to Protect Against Cancer
Therapeutic Cancer Vaccines
Sipuleucel-T (Provenge)
GSK3377794 (NY ESO-1 TCR)
Axalimogene Filolisbac (ADXS11-011)
Axicabtagene Ciloleucel (KTE-C19)
ICT-107
DCVax-L
DPX-Survivac
Other
VEGFR and PDGFR Inhibitors
EGFR and HER2/NEU Inhibitors
Immunomodulators
BCR-ABL Inhibitors
Proteasome Inhibitors
BTK Inhibitors
Expanded Information on Selected Product Candidates and Recent Regulatory Applications
Midostaurin
Lartruvo (Olaratumab)
Inotuzumab Ozagamicin
Sacituzumab Govitecan (IMMU-132)
Epacadostat
Chapter 5 Oncolytic Virology
Oncolytic Virotherapy
T-VEC (Talimogene Laherparepvec)
DNX-2401
PEXA-VEC (Pexastimogene Devacirepvec)
CAVATAK (CVA21)
Reolysin
Enadenotucirev (ColoAd1)
GL-ONC1
TELOMELYSIN (OBP-301)
HF10
WO-12
Chapter 6 Major Markets
Markets for Immunotherapy Products
Markets for Oncolytic Virology Products
Chapter 7 Company Profiles
ABBVIE INC.
ADAPTIMMUNE
ADURO BIOTECH
ADVANTAGENE
ADVAXIS IMMUNOTHERAPIES
AMGEN
ARGOS THERAPEUTICS
ARIAD PHARMACEUTICALS
AROG PHARMACEUTICALS
ASERTA PHARMACEUTICALS
ASTELLAS
ASTRAZENECA
AVAX TECHNOLOGIES
BAVARIAN NORDIC
BAYER HEALTHCARE
BIOVEX
BOEHRINGER INGELHEIM
BOSTON BIOMEDICAL
BRISTOL-MYERS SQUIBB
CELL MEDICA
CELLDEX THERAPEUTICS
CELGENE CORP.
CHUGAI
COLD GENESYS
DAIICHI SANKYO CO.
DENDREON
DNATRIX
EISAI
ELI LILLY
F HOFFMANN LA ROCHE AG
GENELUX
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
HANMI PHARMACEUTICAL
HEAT BIOLOGICS
IMMUNE DESIGN
IMMUNOCELLULAR THERAPEUTICS LTD.
IMMUNOMEDICS INC.
IMMUNOVACCINE INC.
IMMUNOVATIVE THERAPIES
INCYTE CIORP.
INOVIO PHARMACEUTICALS INC.
JANSSEN PHARMACEUTICALS
KADMON PHARMACEUTICALS CORP.
KITE PHARMACEUTICALS INC.
KYOWA HAKKO KIRIN CO. LTD.
LIGAND PHARMACEUTICALS INC.
LION BIOTECHNOLOGIES
LOKON PHARMACEUTICALS AB
MEDIMMUNE
MERCK & CO.
MERCK KGAA
MERCK SERONO
MEDIGENE AG
MIRATI THERAPEUTICS
MULTIVIR INC.
NEWLINK GENETICS
NORTHWEST BIOTHERAPEUTICS
NOVARTIS PHARMA SERVICES AG
ONCOLYS BIOPHARMA INC.
ONCOLYTICS BIOTECH INC.
ONCOMED PHARMACEUTICALS INC.
ONCOS THERAPEUTICS LTD.
ONO PHARMACEUTICAL CO.
OTSUKA PHARMACEUTICAL CO., LTD.
PFIZER INC.
PLEXXIKON INC.
PORTOLA PHARMACEUTICALS INC.
PROVECTUS BIOPHARMACUETICALS INC.
PSIOXUS THERAPEUTICS LTD.
SANOFI SA
SEATTLE GENETICS
SHANGHAI SUNWAY BIOTECH CO. LTD.
SHENZHEN SIBIONO GENTECH
SILLAJEN BIOTHERAPEUTICS INC.
SPECTRUM PHARMACEUTICALS
TAKARA BIO INC.
TAKEDA CO. LTD.
TAPIMMUNE INC.
TARGOVAX
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TG THERAPEUTICS INC.
TRACON PHARMACEUTICALS INC.
TRANSGENE
VCN BIOSCIENCES
VENTIRX
VERASTEM INC.
VIRALYTICS LTD.
VIRTTU BIOLOGICS LTD
VYRIAD
WESTERN ONCOLYTICS LTD.
Trends Market Research © Copyright 2020. All Rights Reserved.